Making medicines safer - The need for an independent drug safety board

New England Journal of Medicine

Volumn 339, Issue 25, 1998, Pages 1851-1854

  Wood, Alastair J J ^a   Stein, C Michael ^a   Woosley, Raymond ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENOXAPROFEN; DEXFENFLURAMINE; ENCAINIDE; MIBEFRADIL; SILDENAFIL; TERFENADINE; TIENILIC ACID; TROGLITAZONE; ZOMEPIRAC;

DRUG APPROVAL; DRUG MARKETING; DRUG MONITORING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEART VENTRICLE TACHYCARDIA; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; TORSADE DES POINTES; VALVULAR HEART DISEASE;

CONFLICT OF INTEREST; DEXFENFLURAMINE; DRUG APPROVAL; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; SEROTONIN AGONISTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0032542251     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199812173392512     Document Type: Review

References (13)

1. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8. [Erratum, N Engl J Med 1997;337:1783.]
2. Johannes L. New diet-drug data spark more controversy. Wall Street Journal. October 1, 1997:B1.
3. Johannes L, Stecklow S. Heart valve problem that felled diet pills arose earlier abroad. Wall Street Journal. December 11, 1997:A1, A13.
4. Moore SD, Winslow R. Roche recalls drug to reduce blood pressure. Wall Street Journal. June 9, 1998:B1, B25.
5. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-5.
6. Khan MA, Herzog CA, St Peter JV, et al. The prevalence of cardiac-valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 1998;339:713-8.
7. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998;339:719-24.
8. Langreth R, Johannes L. Diet drug mystery grows as new data emerges. Wall Street Journal. October 31, 1997:B1.
9. Air Transport Association data & statistics. (See: http://www.airtransport.org/data/safety.htm.) (Also available from NAPS, c/o Microfiche Publications, P.O. Box 3513, Grand Central Station, New York, NY 10163-3513.)
10. Angell M. Evaluating the health risks of breast implants: the interplay of medical science, the law, and public opinion. N Engl J Med 1996;334:1513-8.
11. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-31.
12. Opie LH, Messerli FH. Nifedipine and mortality: grave defects in the dossier. Circulation 1995;92:1068-73.
13. Messerli FH. Case-control study, meta-analysis, and bouillabaisse: putting the calcium antagonist scare into context. Ann Intern Med 1995;123:888-9.